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in the text. Dr Kirkwood suggests that there are a number of
‘errors’ in the editorial, but provides no evidence for these,
although there is a difference in our interpretations of the available
data, which is incomplete. In the absence of the definitive report
on E1690 it is reasonable to speculate that stage migration and
changes in surgical technique might explain the difference
between the results and those of E1684. Dr Kirkwood points out
one such change in that twice as many patients had clinically
negative unresected lymphatics in the later study. Only he can
appreciate the role, if any, of sentinel node biopsy until the E1690
results are published.
The editorial acknowledges that overall survival was improved
by high-dose interferon (HDI) in the original study. Amongst the
four sub-groups analysed in the trial report only patients with clin-
ically apparent lymphadenopathy showed a statistically significant
improvement in survival. It is fair to say that the group with clini-
cally negative histologically positive nodes was too small to allow
interpretation of interferon’s efficacy. However, to maintain that
this is the population with the most to gain from HDI on the basis
of a 34 patient sample is tenuous, and not a claim Dr Kirkwood
made in the original report on E1684.
We are agreed that HDI is active in melanoma, and that cross-
over salvage therapy is the most plausible explanation for the
conflicting results obtained. Given its toxicity and the suggestion
that it remains effective at second relapse further work is
required to pinpoint the role of HDI in melanoma. Thus, it is not
possible to commend HDI as the standard adjuvant therapy in
melanoma at high risk of recurrence. Indeed, various cooperative
groups are pursuing trials in this field in which the control arm is
observation only and Schering Plough recently abandoned their
study in resected stage III melanoma in which HDI was the
control arm.
Patients should undoubtedly be informed of the results of both
trials, but only in the USA will they be permitted to accept or
reject treatment. The conflicting results of the E1684 and E1690
studies mean that few purchasers in the UK currently funds HDI
for melanoma at high risk of recurrence. Only patients with the
means to fund treatment themselves will be able to come to their
own decision. The way forward is to design and execute studies
that address the issues thrown up by the imminent publication of
the full E1690 results.
MR Middleton
CRC Department of Medical Oncology,
Christie Hospital NHS Trust, Wilmslow Road,
Withington, Manchester M20 4BX, UK
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Serum tissue polypeptide-specific antigen (TPS):
what is its diagnostic value?
Sir,
We have read with interest an article of Rebhandl et al (1998) on
the diagnostic usefulness of the tissue polypeptide-specific antigen
(TPS) in neuroblastoma and Wilms tumour. We would like to
share our clinical experience with TPS, which is less convincing
than that presented, and have a comment to add on the theoretical
and technical part of the paper.
Traditionally, TPA – summing fragments of (cyto)keratins 8, 18,
19 – and TPS – the soluble fragment of (cyto)keratin 18 – have
been interpreted by some researchers as markers for cell prolifera-
tion (Einarsson and Rylander, 1997; Mishaeli et al, 1998). With the
advent of knowledge on apoptosis it has been found that one of the
central effector molecules, caspase-3, utilizes (cyto)keratin 18 but
not (cyto)keratin 8 as a substrate (Caulin et al, 1997). This recent
observation implies that (cyto)keratin 18 may be specifically
degraded upon receiving an apoptotic stimulus, thus putatively
producing a TPS-like material. We currently explore this concept
on the MCF-7 breast cancer-derived cell line, which is deficient in
caspase-3 (Janicke et al, 1998). Altogether, tumour markers based
on detection of (cyto)keratin fragments, TPA, TPS and CYFRA21-
1 may, at least to some extent, reflect degradative rather than
proliferative cellular events. Apoptosis-inducing antitumour
therapy (cytotoxic drugs, radiotherapy) leads to downstream acti-
vation of caspase-3 in most systems studied (Hannun, 1997). The
question of cleavage products of this reaction with (cyto)keratin
18 as a substrate has not yet been addressed.
In the presence of sepsis and/or renal insufficiency, TPS values
are indeed elevated. However, minor or localized infection and
liver and/or multiorgan failure can also lead to elevation of TPS
with either no apparent underlying malignancy or no change in
stable disease, as we have repeatedly observed in our patients. The
authors state, that ‘these samples were, therefore, excluded’
without giving specific criteria. It should be noted that TPA/TPS
are fairly unspecific biomarkers and for diagnosis are of similar
value as erythocyte sedimentation rate. We assume that diagnoses
in these patients were based on standard techniques. In this sense,
interpreting TPS as a diagnostic marker and assessing its speci-
ficity using ROC after careful a priori elimination of confounders
seems inappropriate, since the TPS value apparently adds nothing
to the diagnostic procedure. On the other hand, data from Table 1
of the paper indicate that TPS could be interpreted as a therapy
response marker (Pronk et al, 1997) as long as variables (intercur-
rent infections, etc.) are under control. It would also be informa-
tive to include comparison with established biomarkers for
neuroblastoma and Wilms’ tumour (catecholamines, NSE). That
‘the potential of TPA in Wilms’ tumour (Ishiwata et al, 1991) have
gone unnoticed in the literature’, as the authors state, may merely
reflect the fact that the TPA value has never contributed new and
clinically relevant information.
At our institute, we performed measurement of TPA for about
8 years (approx. 5500 measurements year–1); 7 months ago we
replaced TPA with TPS Beki (Sweden) due to automation andavoidance of radioactivity. We used both mostly as disease recur-
rence markers for adult patients with solid tumours, mainly breast
and colorectal cancers, believing, as others, that this reflects the
proliferative status of the particular tumour (Nekulova et al, 1995;
Van Dalen et al, 1998; Nisman et al, 1998). We have abandoned
the practice of monitoring patients with TPS (ASCO, 1997) after 7
months when we had completed 2703 tests. During this time we
observed isolated elevation of TPS higher than 140 U l–1, in 61
patients (breast and colorectal cancer), with other relevant markers
(CA15-3, CEA, CA19-9) being below cutoff. In only four of them
recurrence of disease was confirmed (breast cancer assessed by
CA15-3, CEA, imaging techniques and complete examination by a
medical oncologist). In two other patients (breast cancer) a suspect
finding appeared on bone gallium scan, which was not subse-
quently confirmed on CT scan. Another two patients presenting
with elevation of TPS were classified as stable disease (breast
cancer, local partial remission). In another 55 patients restaging
was performed at the discretion of a medical oncologist in charge,
however, without contributing new information.
Especially data on TPS elevations approaching up to 2600 U l–1
with no apparent disease progression in patients otherwise classi-
fied as ‘complete remission’ added significant stress to patients
and their doctors and generated substantial unnecessary testing.
Although inconclusive at this point, this group of false positives
suffered mostly from chronic inflammatory and/or noninflamma-
tory skin affections (herpetic infections, unhealed defects after
radiotherapy with or without secondary bacterial infections and in
some the reason was not apparent). In clinical practice the true
difference between ‘false positivity’ and ‘lead time’ is difficult to
distinguish during a limited time period; those markers with lead
times longer than 7 months do not prove very useful for influ-
encing patient outcome – this may obviously be the case of some
of our 55 patients. It is our belief that the validity of new
biomarkers and reevaluation of those used previously (Robertson,
1998) should be critically reassessed on a periodic basis if the
ultimate goal is to improve patient care while avoiding unneces-
sary increases in noise and cost of health care. In agreement with
the authors of the present paper, we currently recognize the poten-
tial of serum TPS only as a marker for monitoring response to
cytotoxic therapy in explicitly defined diagnostic groups and when
the potential of administering curative therapy exists, which
indeed may include neuroblastoma and Wilms’ tumor. In our
opinion, TPS should not be used as a diagnostic marker and only in
exceptional cases as a marker for disease recurrence.
D Valik, M Nekulova
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Response to: Serum tissue polypetide-specific antigen
(TPS): what is its diagnostic value — reply
Sir,
We are glad that our paper (Rebhandl et al, 1998) has aroused the
interest of Drs Valik and Nekulova and that they can agree with
our conclusions regarding the potential of TPS as a tool for moni-
toring therapy response. However, we would like to make a few
comments on this letter.
First of all, our paper did not report clinical experience. The
situation in paediatric oncology is very different from adult
oncology. Apart from catecholamines and NSE in neuroblastoma
(not in Wilms’ tumor) there are no ‘established’ tumour-markers.
For TPS we actually had to establish normal values for healthy
children (Rebhandl et al, 1997) before addressing patients with
malignant disease. Furthermore, all our data are based on TPS and
not on TPA, which in our opinion is not comparable.
Breast and colorectal cancer are among the most frequent
malignant diseases in the western world, while the incidence of
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